Exane Derivatives’s ANI Pharmaceuticals ANIP Stock Holding History

Exane Derivatives’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$148	Sell	5 -20	-80%	-$577	﹤0.01%	699
2022 Q1	$703	Hold	25	–	–	﹤0.01%	837
2021 Q4	$1.15K	Hold	25	–	–	﹤0.01%	692
2021 Q3	$820	Sell	25 -4,339	-99%	-$135K	﹤0.01%	885
2021 Q2	$147K	Buy	4,364 +4,355	+48,389%	+$148K	0.03%	485
2021 Q1	$325	Sell	9 -158	-95%	-$4.95K	﹤0.01%	837
2020 Q4	$4.85K	Buy	+167	New	+$4.78K	﹤0.01%	560

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Exane Derivatives's ANIP Position: Q2 2022 in Review

Exane Derivatives reduced its ANI Pharmaceuticals (ANIP) stake by 80% in Q2 2022, selling an estimated $577 and leaving 5 shares worth $148. The position accounts for ﹤0.01% of the portfolio, ranked #699.

Exane Derivatives first reported a position in ANIP in Q4 2020 and has held it in 7 quarters since. The position peaked at $147K in Q2 2021. 120 funds tracked by Wall St. Rank hold ANIP as of Q2 2022.

Exane Derivatives held 5 shares of ANI Pharmaceuticals worth $148 as of Q2 2022.
Exane Derivatives sold 20 ANI Pharmaceuticals shares in Q2 2022, an estimated $577.
ANI Pharmaceuticals made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #699 holding.
Exane Derivatives first reported a position in ANI Pharmaceuticals in Q4 2020 and has held it in 7 quarters since.
Exane Derivatives's ANI Pharmaceuticals position peaked at $147K in Q2 2021.
120 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.